Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Klin Onkol ; 32(6): 456-462, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31842565

RESUMEN

BACKGROUND: Oncological diseases have, in most cases, a multifactorial etiology, composed of a combination of external and internal environmental factors. Hereditary tumorous syndromes are mostly autosomal dominant diseases with incomplete but very high penetrance. OBSERVATION: The patient, an 18-year-old virgin female, consulted a gynecologist in June 2018 because of metrorrhagia. Magnetic resonance imaging revealed a cervical tumor with the dimensions 80 × 90 × 80 mm. Histological analysis confirmed the presence of a very rare hypercalcemic type of small-cell carcinoma of the cervix. Further investigation of the germinal exom of the patient showed pathological variations in genes PALB2 and BRCA2, presented with recommendation of detailed examination by medical genetics. CONCLUSION: Clinical experience with this type of tumor is very limited, but it still comes with some useful outcome. Small cell carcinomas of the gynecologic tract are very rare, aggressive diseases, with very poor prognosis, affecting mainly young women. Their origin is most often the ovaries, based on most clinical data, but these tumor also localize to the endometrium, cervix, vagina and vulva. It is an extremely rare type of cancer, for which clinical data is scant due to the extremely low number of reported cases. In this patient, the carcinoma had an unusual genetical mutation burden, which she inherited from her parents. In the light of these findings, we recommend that patients suspected of having a small-cell of the gynecologic tract provide a detailed family history, and that genetic testing be considered in similar cases. This work was supported by MH CR grant 16-33209A and research program of Charles University Progress Q40/06. The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers. Submitted: 10. 6. 2019 Accepted: 9. 9. 2019.


Asunto(s)
Proteína BRCA2/genética , Carcinoma de Células Pequeñas/genética , Proteína del Grupo de Complementación N de la Anemia de Fanconi/genética , Hipercalcemia/genética , Neoplasias del Cuello Uterino/genética , Adolescente , Carcinoma de Células Pequeñas/diagnóstico por imagen , Carcinoma de Células Pequeñas/patología , Femenino , Humanos , Hipercalcemia/diagnóstico por imagen , Hipercalcemia/patología , Imagen por Resonancia Magnética , Mutación , Neoplasias del Cuello Uterino/diagnóstico por imagen , Neoplasias del Cuello Uterino/patología
2.
Ceska Gynekol ; 78(3): 257-62, 2013 Jun.
Artículo en Checo | MEDLINE | ID: mdl-23869832

RESUMEN

OBJECTIVE: To provide an actual review of radiotherapy in the treatment of vulvar carcinoma. DESIGN: A review article. SETTING: Department of Oncology and Radiotherapy, University Hospital in Hradec Králové. METHODS: A review article evaluating the application of ionizing radiation in the treatment of early and advanced vulvar carcinoma, based on the most significant previously published studies. CONCLUSION: Postoperative groin irradiation in patients with positive groin lymph-nodes improves local control, time to progression, and overall survival; especially in 2 positive nodes and in N2/3 initial findings. In case of positive inguinal nodes, radiotherapy of both groins and at least lower pelvic iliac node-chains should follow. Adjuvant irradiation of the primary remains controversial, except for positive resection margins where radiotherapy improves overall survival. Concurrent chemoradiotherapy seems to be appropriate primary treatment of advanced vulvar carcinomas, in attempt to avoid mutilating intervention or exenteration. Chemoradiation should be followed by subsequent surgery, including potential groin dissection in case of lymph-node involvement. Definitive chemoradiotherapy is of limited evidence, and radical dose escalation to the gross tumor is essential for its implementation. Modern radiotherapy techniques, especially with intensity modulation, are convenient for dose escalation.


Asunto(s)
Neoplasias de la Vulva/radioterapia , Biopsia , Quimioradioterapia , Femenino , Ingle/patología , Ingle/cirugía , Humanos , Ganglios Linfáticos/patología , Ganglios Linfáticos/cirugía , Persona de Mediana Edad , Neoplasias de la Vulva/tratamiento farmacológico , Neoplasias de la Vulva/mortalidad , Neoplasias de la Vulva/cirugía
3.
Neoplasma ; 56(2): 163-8, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19239332

RESUMEN

UNLABELLED: Low dose rate (LDR) brachytherapy is a well established treatment for the early stages of tongue cancer. High dose rate (HDR) afterloading devices have replaced LDR brachytherapy in many radiotherapy departments, but the effect and safety of HDR brachytherapy in comparison with LDR brachytherapy for interstitial applications is an unresolved question. The aim of our radiobiological study was to utilize dose volume histiograms from patients treated in our institution to simulate the risk of complication of LDR and HDR brachytherapy. Normal tissue complication probabilities (NTCP) of acute mucositis, late mucosal necrosis and osteoradionecrosis of two HDR brachytherapy schedules (18 x 3 Gy bid and 10 x 6 Gy bid) and of LDR brachytherapy with identical tumor control probability were compared using data from 8 brachytherapy applications. A linear quadratic (LQ) model was used to calculate the biologically equivalent doses, the effective volume method of Kutcher and Burman and Lyman's model was used to calculate NTCP. The Student's two-tailed test was used for statistical analysis. For 18 x 3 Gy bid the risk of acute mucositis and of late mucosal necrosis was 1.48 and 1.66 times higher with HDR in comparison with LDR brachytherapy. For 10 x 6 Gy bid the risk of acute mucositis, mucosal necrosis and osteoradionecrosis was 1.3, 3.44 and 13.18 times higher with HDR brachytherapy. All differences were statistically highly significant. Our radiobiological study supported the hypothesis that HDR has a higher risk of complication in comparison with LDR brachytherapy for the same tumor control probability. KEYWORDS: tongue cancer, brachytherapy, low dose rate, high dose rate.


Asunto(s)
Braquiterapia , Neoplasias de la Lengua/radioterapia , Braquiterapia/efectos adversos , Braquiterapia/métodos , Relación Dosis-Respuesta en la Radiación , Humanos , Dosificación Radioterapéutica
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...